1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow YOUNGIL KOH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma Elranatamab, Mezigdomide, Dexamethasone - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | Recruiting | YOUNGIL KOH | 75 | 2024-11-26 | 2025-12-03 |
Multiple Myeloma (1)
Dexamethasone (1)
Singapore (1) · South Korea (1)